Open | 2.30 |
Previous Close | 2.35 |
Day Range | 2.26 - 2.50 |
52-Week Range | 1.50 - 5.87 |
All-Time High | 202.00 |
Avg. Volume (50-day) | 1,572,909.4 |
EPS (TTM) | -0.02 |
Next Earnings Date | - |
Last Earnings Date | - |
Forward Annual Dividend (Yield) | - |
Trailing Annual Dividend (Yield) | - |
Options | No |
P/E Ratio | -0.98 |
PEG Ratio | 0.88 |
Price to Book | 43.64 |
Price to Cash Flow | - |
Price to Free Cash Flow | - |
Total Sales (TTM) | 25.12 M |
Revenue per Share (TTM) | - |
Shares Outstanding | 1.042 B |
Share Float (%) | 381.46 M |
% Held by Institutions | 14.61 |
Dividends Per Share (TTM) | - |
Ex-Dividend Date | - |
+/- EMA(20) | 2.54 (-4.72%) |
+/- SMA(50) | 2.82 (-14.18%) |
+/- SMA(200) | 3.25 (-25.54%) |
5-Day Perf. | +0.83% |
1-Month Perf. | -8.68% |
3-Month Perf. | -41.55% |
6-Month Perf. | -10.37% |
YTD Perf. | -10.37% |
1-Year Perf. | +34.44% |
RSI(14) | 43.77 |
ATR(14) | 0.24 |
ADX(14) | 33.76 |
Beta (5Y) | 0.26 |
Shield Therapeutics Plc is a commercial stage specialty pharmaceutical company, which engages in addressing iron deficiency with its lead product Accrufer. It operates the Feraccru and PT20 segments. The Feraccru segment refers to the development and commercialization of this product. The PT20 segment related to the development of its secondary asset. The company was founded by Carl Sterritt and Christian Schweiger in 2008 and is headquartered in Gateshead Quays, the United Kingdom.
STX.L has triggered the following predefined scans:
No Recent Scan Appearances |
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.